Cover Image
市場調查報告書

全球DPP IV 抑制劑市場

DPP IV Inhibitors

出版商 Global Industry Analysts, Inc. 商品編碼 222501
出版日期 內容資訊 英文 192 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球DPP IV 抑制劑市場 DPP IV Inhibitors
出版日期: 2016年04月01日 內容資訊: 英文 192 Pages
簡介

本報告提供全球DPP IV 抑制劑市場相關調查,彙整各地區趨勢與2015∼2022年的市場成長預測,及加入此市場的主要企業簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • DPP IV 治療今後預測將穩定發展
    • DPP IV 抑制劑領域的主要活動
    • 由TECOS的結果所顯示的Gliptin中Januvia的優勢
    • Januvia等DPP-4抑制劑的莫大可能性
    • 糖尿病的流行病學
    • 抗糖尿病藥物類別的藥物類別概要 其他
  • 核準的藥物及開發平台分析
  • 糖尿病發病率及罹患率
    • 全球糖尿病數量
    • 北美
    • 歐洲
    • 亞太地區
    • 南美·中美
    • 其他
  • DPP-IV抑制劑:藥物類別概要
  • 產品認證/簡介
  • 主要企業
    • AstraZeneca Plc.
    • Boehringer Ingelheim GmbH
    • Eli Lilly and Company
    • Merck & Co, Inc.
    • 田邊三菱製藥株式會社
    • Novartis AG (Switzerland)
    • 武田藥品工業株式會社
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 其他

競爭環境

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6466

This report analyzes the worldwide markets for DPP IV Inhibitors in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and number of prescriptions, by the following Drug Segments: Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 23 companies including many key and niche players such as -

AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck & Co, Inc.
Mitsubishi Tanabe Pharma Corporation

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Outlook for DPP-IV Therapies Remains Robust
  • Major Events in the DPP-IV Inhibitor Space
    • Table 1: Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
  • TECOS Results Prove Superiority of Januvia among Gliptins
  • Huge Potential Exists for Januvia and Other DPP-4 Inhibitors
    • Table 2: Global DPP-4 Inhibitor Market by Top Five Drug Class (2015): Percentage Market Share Breakdown of Revenues (includes corresponding Graph/Chart)
  • The Diabetes Epidemic
  • Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market
    • Table 3: Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 Years to Treat Diabetes and Manage Associated Complications (includes corresponding Graph/Chart)
  • Overview of Drug Classes in Anti-Diabetic Drugs Category
  • Complicated T2DM Management Protocol and the Role of DPP-IV Inhibitors
  • DPP-4 Inhibitors - Complementing Existing Approaches
  • Rationale for Use of DPP-4 Inhibitors
  • Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction
  • Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market
  • DPP-4 Inhibitors versus GLP-1 Receptor Agonists
  • Distinction between GLP-1 Receptor Agonists and DPP-4 Inhibitors
  • DPP-4 Inhibitors versus Sulfonylureas

2. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS

  • The DPP-4 Inhibitor Domain
  • Select Approved DPP-4 Inhibitors Available in Developed Markets
  • Januvia - The Leading DPP-IV Inhibitor Drug Worldwide
  • Galvus Sales Garner Significant Growth
  • A Comparison of Januvia and Galvus
  • Pharmacological Comparison of Sitagliptin and Vildagliptin
  • Januvia(r) Franchise (Merck & Co.)
    • Table 4: Global Sales of Januvia (Sitagliptin) Franchise by Region (2016E, 2018E, 2020E & 2022E): Value Sales in US$ Million for US and RoW(includes corresponding Graph/Chart)
  • Implantable Drug Pump: Potential Threat to Januvia?
  • Galvus (Novartis)
  • Onglyza (AstraZeneca)
    • Table 5: Global Sales of Onglyza (Saxagliptin) Franchise by Region (2016, 2018, 2020 & 2022): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart)
  • Tradjenta (Boehringer Ingelheim)
  • TENELIA (Mitsubishi Tanabe Pharma Corporation & Daiichi Sankyo Co., Ltd.)
  • Nesina (Takeda Pharmaceutical)
  • ZAFATEK (Takeda Pharmaceutical)
  • MARIZEV (Merck)
  • Pipeline Analysis
  • DPP-IV Inhibitor Pipeline
  • Dutogliptin Development Shelved

3. DIABETES INCIDENCE AND PREVALENCE

    • Table 6: Global Diabetes Mellitus Incidence among Ages 20-79 (2015 & 2040P): Prevalence (in Million) and Percentage Share by Geographic Region (includes corresponding Graph/Chart)
    • Table 7: Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2015 (includes corresponding Graph/Chart)
  • Diabetes Mellitus Cases Worldwide - A Demographic Analysis by Geographic Region
  • North America
    • The United States
    • Canada
    • Mexico
    • Table 8: Prevalence of Diabetes Mellitus in North America (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for the US, Canada and Mexico (includes corresponding Graph/Chart)
  • Europe
    • Table 9: Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region
  • Asia-Pacific
    • Table 10: Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka
    • Table 11: Prevalence of Diabetes Mellitus in Western Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
  • South & Central America
    • Table 12: Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region
  • Rest of World
    • Table 13: Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
    • Table 14: Prevalence of Diabetes Mellitus in The Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region

4. DPP-IV INHIBITORS - AN OVERVIEW OF THE DRUG CLASS

  • Physiology of Glucose Homeostasis
  • Glucose Homeostasis in the Fasting Stage
  • Glucose Homeostasis in the Fed Stage
  • What is DPP-4?
  • Introduction to DPP-4 Inhibitors
  • Mechanism of Action of DPP-4 Inhibitors
  • Schematic Representation of DPP-IV Inhibitor' Mechanism of Action
  • DPP-4 Inhibitors in Combination with Other Anti-diabetic Medications
  • Advantages of DPP-4 Inhibitors
  • Type-2 Diabetes - The Most Prevalent Form of Diabetes
  • Bio-chemistry of T2DM

5. PRODUCT APPROVALS/INTRODUCTIONS

  • Mankind Pharma Launches Affordable Teneligliptin Drug
  • Zydus Cadila to Launch Tenglyn
  • Dong-A ST's Evogliptin Drug SUGANON Receives Approval
  • PMDA Approves Merck's MARIZEV(r) (omarigliptin) for Type 2 Diabetes
  • Glenmark Launches Teneligliptin under Ziten and Zita Plus Brands
  • Takeda Launches ZAFATEK
  • FDA Approves Glyxambi (linagliptin) by Boehringer and Lilly
  • EC Approves Takeda's Alogliptin Fixed-Dose Combination Therapies
  • Mitsubishi Receives Approval for Partial Change in Indication for TENELIA
  • CFDA Approves Takeda's NESINA
  • USFDA Approves Takeda's NESINA, KAZANO and OSENI

6. RECENT INDUSTRY ACTIVITY

  • FDA Issues Heart Failure Risk Warning to Saxagliptin and Alogliptin Medicines
  • First Real-world Evidence Hints at Greater Efficacy of SGLT2 Inhibitors
  • FDA Issues CRL to AstraZeneca Regarding Investigational Drug
  • Lupin and Boehringer Announce Co-Marketing Agreement
  • FDA Issues Safety Warning about DPP-4 Inhibitors
  • Merck's TECOS Trial Meets Primary Endpoint
  • AstraZeneca Enters into Distribution Agreement with Dr.Reddy's
  • AstraZeneca Files Lawsuit against Mylan for Patent Violation on Onglyza
  • BMS Completes Sale of Diabetes Business to AstraZeneca
  • Merck to Discontinue JUVISYNC Distribution to Pharmacies
  • Takeda and Sanofi Sign Co-Agreement to Market Alogliptin in China
  • Otsuka Pharmaceutical Receives Marketing Approval for Onglyza

7. FOCUS ON SELECT GLOBAL PLAYERS

  • AstraZeneca Plc. (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co, Inc. (US)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Novartis AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)

8. GLOBAL MARKET PERSPECTIVE

    • Table 15: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 16: World Historic Review for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 17: World 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 18: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 19: World Historic Review for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 20: World 14-Year Perspective for DPP-IV Inhibitors by Drug Class - Percentage Breakdown of Dollar Sales for Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • DPP-4 Inhibitors Set to Gain High Share in US Oral Anti-Diabetic Market
      • List of FDA-Approved DPP-4 Inhibitors in the US: 2016
    • Diabetes Pandemic in the US
    • Table 21: Prevalence of Diabetes Mellitus in the US (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group (includes corresponding Graph/Chart)
    • Categories in Diabetes Treatment Market
    • Table 22: The US Anti-Diabetic Market by Drug Class (2015): Percentage Share Breakdown of Revenues for Insulin, DPP-4 & SGLT-2 Inhibitors, GLP-1 Analogues, Glitazones, PPARs, and Biguanides (includes corresponding Graph/Chart)
    • Increased Diabetes Spending Favors the DPP-4 Inhibitor Market
    • Januvia Leads the Way, Will Continue to Maintain Dominance Through 2022
    • Table 23: The US DPP-4 Inhibitors Market by Leading Brands (2016): Percentage Market Share Breakdown of Revenues for Januvia, Janumet, Tradjenta, Onglyza, Janumet XR, Kombiglyze, and Others (includes corresponding Graph/Chart)
    • Minimal Differentiation Affects Sales of Onglyza
    • Table 24: The US Anti-Diabetes Drugs in terms of Total Prescriptions (2015): Percentage Share of Metformin, Sulfonylureas, and DPP-4 Inhibitors (Januvia, Onglyza, Tradjenta & Other) to the Total Non-Insulin Prescriptions (includes corresponding Graph/Chart)
    • FDA's Issue of Safety Warning on DPP-4 Inhibitors - Potential Market Threat
    • Increasing Scrutiny of NDAs Delays Time-to- Market for New Drugs
    • Product Approvals
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 25: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 26: The US Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 27: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 28: The US 7-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 29: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitor Prescriptions by Drug Compound: Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Number of Prescriptions in Thousands for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 30: The US 7-Year Perspective for DPP-IV Inhibitors Prescriptions by Drug Compound - Percentage Breakdown of Prescriptions for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Table 31: Prevalence of Diabetes Mellitus in Canada (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for Canada (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 32: Canadian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 33: Canadian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Japan - An Important Market for DPP-IV Inhibitors
    • Table 34: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Competition in the Japanese DPP-IV Inhibitor Market Heats Up
      • List of DPP-4 Inhibitors in the Japanese Market (2016)
    • Product Approvals/Launches
    • Select Key Players
  • B. Market Analytics
    • Table 35: Japanese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 36: Japanese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
      • DPP-IV Inhibitors Available in the European Market
    • Prevalence of Diabetes in Europe: Aging Population Dominate
    • Table 37: Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region
    • Treatment Strategies of Type-2 Diabetes in Europe
    • Product Approval
  • B. Market Analytics
    • Table 38: European Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 39: European Historic Review for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 40: European 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Russia, and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • Market Analysis
    • Table 41: French Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 42: French Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Boehringer Ingelheim GmbH - A Key Player
  • B. Market Analytics
    • Table 43: German Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 44: German Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 45: Italian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 46: Italian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Strategic Corporate Development
    • Astrazeneca plc. - a key player
  • B. Market Analytics
    • Table 47: The UK Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 48: The UK Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. RUSSIA

  • Market Analysis
    • Table 49: Russian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 50: Russian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Novartis Ag - A Key Switzerland-Based Player
  • B. Market Analytics
    • Table 51: Rest of European Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 52: Rest of European Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Asia-Pacific: The Fastest Growing Market for DPP-IV Inhibitors
    • Aging Populace - Potential Opportunities
    • Table 53: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart)
    • China & India Offer High Potential
    • Rising Diabetes Incidence in Asia-Pacific Offers Significant Growth Opportunities
    • Table 54: Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka
    • Table 55: Prevalence of Diabetes Mellitus in Western Asia-Pacific Regions (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
    • Asia Suffers from Lack of Focus on Diabetes Care
    • Healthcare Societies and Associations Spread Awareness of Diabetes
  • B. Market Analytics
    • Table 56: Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 57: Asia-Pacific Historic Review for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 58: Asia-Pacific 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for China, India, South Korea, and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current & Future Analysis
      • China: A Market with Huge Untapped Potential for DPP-4 Inhibitor Drugs
    • Robust Growth Ahead Despite Initial Lag
    • Product Approval
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 59: Chinese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 60: Chinese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • DPP-4 Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market
    • First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition
    • Diabetic Epidemic in the Country Spurs Market Growth
    • Product Launches
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 61: Indian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 62: Indian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5c. SOUTH KOREA

  • A. Market Analysis
    • Rising Competition in the Korean DPP-4 Inhibitor Market
    • Table 63: Korean DPP-4 Inhibitor Market (2009-2015): No. of DPP-4 Inhibitors on the Market during 2009, 2010, 2011, 2012, 2013, 2014 & 2015 (includes corresponding Graph/Chart)
    • Product Approval
  • B. Market Analytics
    • Table 64: South Korean Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 65: South Korean Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5d. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Australia
      • Rising Incidence of Diabetes
  • B. Market Analytics
    • Table 66: Rest of Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 67: Rest of Asia-Pacific Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
    • Latin America: National Diabetes Programs
    • A Peek at Brazilian Diabetes Market
    • Table 68: Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region
    • United Arab Emirates: Rising Diabetic Cases to Propel Market Demand
    • Key Statistics: Diabetes Prevalence in Middle East and African Regions
    • Table 69: Prevalence of Diabetes Mellitus in Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region
    • Table 70: Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
  • B. Market Analytics
    • Table 71: Rest of World Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 72: Rest of World Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top